DIAN DIAGNOSTICS(SZ:300244) Xin Lang Zheng Quan·2025-10-17 05:27Core Viewpoint - The stock of Dian Diagnostics has experienced a decline recently, with a notable drop in trading volume and a significant decrease in revenue and profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2]. - The net profit attributable to shareholders was 10.2772 million yuan, reflecting a substantial year-on-year decrease of 85.68% [2]. - The stock price has increased by 35.78% year-to-date, but has seen declines of 5.81% over the last five trading days, 12.22% over the last 20 days, and 3.77% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average circulating shares per person increased by 12.77% to 10,376 shares [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the last three years [3]. Institutional Holdings - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 14.7985 million shares, an increase of 3.4713 million shares from the previous period [3]. - The third-largest circulating shareholder is the newly entered招商优势企业混合A, holding 11 million shares [3]. - The seventh-largest shareholder, 南方中证1000ETF, increased its holdings by 872,500 shares to 4.6097 million shares [3].